118 related articles for article (PubMed ID: 12736670)
41. Calculation of absolute protein-ligand binding constants with the molecular dynamics free energy perturbation method.
Woo HJ
Methods Mol Biol; 2008; 443():109-20. PubMed ID: 18446284
[TBL] [Abstract][Full Text] [Related]
42. Analysis and optimization of structure-based virtual screening protocols (1): exploration of ligand conformational sampling techniques.
Good AC; Cheney DL
J Mol Graph Model; 2003 Sep; 22(1):23-30. PubMed ID: 12798388
[TBL] [Abstract][Full Text] [Related]
43. Comprehensive identification of "druggable" protein ligand binding sites.
An J; Totrov M; Abagyan R
Genome Inform; 2004; 15(2):31-41. PubMed ID: 15706489
[TBL] [Abstract][Full Text] [Related]
44. Analysis of ligand binding to a ribose biosensor using site-directed mutagenesis and fluorescence spectroscopy.
Vercillo NC; Herald KJ; Fox JM; Der BS; Dattelbaum JD
Protein Sci; 2007 Mar; 16(3):362-8. PubMed ID: 17242374
[TBL] [Abstract][Full Text] [Related]
45. A novel computational analysis of ligand-induced conformational changes in the ATP binding sites of cyclin dependent kinases.
Subramanian J; Sharma S; B-Rao C
J Med Chem; 2006 Sep; 49(18):5434-41. PubMed ID: 16942017
[TBL] [Abstract][Full Text] [Related]
46. Combined target-based and ligand-based drug design approach as a tool to define a novel 3D-pharmacophore model of human A3 adenosine receptor antagonists: pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as a key study.
Moro S; Braiuca P; Deflorian F; Ferrari C; Pastorin G; Cacciari B; Baraldi PG; Varani K; Borea PA; Spalluto G
J Med Chem; 2005 Jan; 48(1):152-62. PubMed ID: 15634009
[TBL] [Abstract][Full Text] [Related]
47. Molecular modeling of sigma 1 receptor ligands: a model of binding conformational and electrostatic considerations.
Gund TM; Floyd J; Jung D
J Mol Graph Model; 2004 Jan; 22(3):221-30. PubMed ID: 14629980
[TBL] [Abstract][Full Text] [Related]
48. Studies of the binding and signaling of surface-immobilized periplasmic glucose receptors on gold nanoparticles: a glucose biosensor application.
Andreescu S; Luck LA
Anal Biochem; 2008 Apr; 375(2):282-90. PubMed ID: 18211816
[TBL] [Abstract][Full Text] [Related]
49. Ligand-based structural hypotheses for virtual screening.
Jain AN
J Med Chem; 2004 Feb; 47(4):947-61. PubMed ID: 14761196
[TBL] [Abstract][Full Text] [Related]
50. Interactions between cardiac glycosides and sodium/potassium-ATPase: three-dimensional structure-activity relationship models for ligand binding to the E2-Pi form of the enzyme versus activity inhibition.
Paula S; Tabet MR; Ball WJ
Biochemistry; 2005 Jan; 44(2):498-510. PubMed ID: 15641774
[TBL] [Abstract][Full Text] [Related]
51. Prediction of protein-ligand interactions. Docking and scoring: successes and gaps.
Leach AR; Shoichet BK; Peishoff CE
J Med Chem; 2006 Oct; 49(20):5851-5. PubMed ID: 17004700
[No Abstract] [Full Text] [Related]
52. Identification of multiple allosteric sites on the M1 muscarinic acetylcholine receptor.
Espinoza-Fonseca LM; Trujillo-Ferrara JG
FEBS Lett; 2005 Dec; 579(30):6726-32. PubMed ID: 16310776
[TBL] [Abstract][Full Text] [Related]
53. Principles and methods of docking and ligand design.
Krumrine J; Raubacher F; Brooijmans N; Kuntz I
Methods Biochem Anal; 2003; 44():443-76. PubMed ID: 12647399
[No Abstract] [Full Text] [Related]
54. Binding of TNT to amplifying fluorescent polymers: an ab initio and molecular dynamics study.
Enlow MA
J Mol Graph Model; 2012 Mar; 33():12-8. PubMed ID: 22137031
[TBL] [Abstract][Full Text] [Related]
55. Computational design of Periplasmic binding protein biosensors guided by molecular dynamics.
O'Shea JM; Doerner P; Richardson A; Wood CW
PLoS Comput Biol; 2024 Jun; 20(6):e1012212. PubMed ID: 38885277
[TBL] [Abstract][Full Text] [Related]
56. Computational analysis of structure-activity relationships.
Gedeck P; Kramer C; Ertl P
Prog Med Chem; 2010; 49():113-60. PubMed ID: 20855040
[No Abstract] [Full Text] [Related]
57. Design of protein-ligand binding based on the molecular-mechanics energy model.
Boas FE; Harbury PB
J Mol Biol; 2008 Jul; 380(2):415-24. PubMed ID: 18514737
[TBL] [Abstract][Full Text] [Related]
58. Escherichia [corrected] coli ribose binding protein based bioreporters revisited.
Reimer A; Yagur-Kroll S; Belkin S; Roy S; van der Meer JR
Sci Rep; 2014 Jul; 4():5626. PubMed ID: 25005019
[TBL] [Abstract][Full Text] [Related]
59. [Computational study on drug design and prediction of bioactivity for regulation of non-controlled psychotropic substances].
Kurihara M
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2010; (128):29-33. PubMed ID: 21381392
[TBL] [Abstract][Full Text] [Related]
60. Accommodating protein flexibility in computational drug design.
Carlson HA; McCammon JA
Mol Pharmacol; 2000 Feb; 57(2):213-8. PubMed ID: 10648630
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
